Analysis/NN
of/IN
differences/NNS
in/IN
human/JJ
leukocyte/NN
antigen/NN
between/IN
the/DT
two/CD
Wellcome/JJ
Trust/NN
Case/NN
Control/NN
Consortium/NN
control/NN
datasets/NNS
./.
====================
The/DT
Wellcome/JJ
Trust/NNP
Case/NN
Control/NN
Consortium/NN
(/(
WTCCC/NN
)/)
study/NN
was/VBD
a/DT
large/JJ
genome-wide/NN
association/NN
study/NN
that/IN
aimed/VBD
to/TO
identify/VB
common/JJ
variants/NNS
associated/VBN
with/IN
seven/CD
diseases/NNS
./.
====================
That/DT
study/NN
combined/VBD
two/CD
control/JJ
datasets/NNS
(/(
58C/NN
and/CC
UK/NN
Blood/NN
Services/NNS
)/)
as/IN
shared/VBN
controls/NNS
./.
====================
Prior/JJ
to/TO
using/VBG
the/DT
combined/JJ
controls/NNS
,/,
the/DT
WTCCC/NN
performed/VBN
analyses/NNS
to/TO
show/VB
that/IN
the/DT
genomic/JJ
content/NN
of/IN
the/DT
control/NN
datasets/NNS
was/VBD
not/RB
significantly/RB
different/JJ
./.
====================
Recently/RB
,/,
the/DT
analysis/NN
of/IN
human/JJ
leukocyte/NN
antigen/NN
(/(
HLA/NN
)/)
genes/NNS
has/VBZ
become/VBN
prevalent/JJ
due/JJ
to/TO
the/DT
development/NN
of/IN
HLA/NN
imputation/NN
technology/NN
./.
====================
In/IN
this/DT
project/NN
,/,
we/PRP
extended/VBD
the/DT
between-control/NN
homogeneity/NN
analysis/NN
of/IN
the/DT
WTCCC/NN
to/TO
HLA/NN
./.
====================
We/PRP
imputed/VBD
HLA/NN
information/NN
in/IN
the/DT
WTCCC/NN
control/NN
dataset/NN
and/CC
showed/VBD
that/IN
the/DT
HLA/NN
content/NN
was/VBD
not/RB
significantly/RB
different/JJ
between/IN
the/DT
two/CD
control/JJ
datasets/NNS
,/,
suggesting/VBG
that/IN
the/DT
combined/JJ
controls/NNS
can/MD
be/VB
used/VBN
as/IN
controls/NNS
for/IN
HLA/NN
fine-mapping/VBG
analysis/NN
based/VBN
on/IN
HLA/NN
imputation/NN
./.
====================
Genome-wide/NN
association/NN
studies/NNS
(/(
GWAS/NN
)/)
have/VBP
identified/VBN
many/JJ
genetic/JJ
variations/NNS
influencing/VBG
complex/NN
traits/VBZ
./.
====================
However/RB
,/,
the/DT
variants/NNS
identified/VBD
to/TO
date/NN
only/RB
explain/VBP
a/DT
portion/NN
of/IN
heritability/NN
,/,
possibly/RB
because/IN
there/EX
remain/VBP
many/JJ
unidentified/JJ
variants/NNS
with/IN
small/JJ
effects/NNS
[/(
1,2/NN
]/)
./.
====================
To/TO
detect/VB
associations/NNS
with/IN
small/JJ
genetic/JJ
effects/NNS
,/,
large/JJ
study/NN
cohorts/VBZ
are/VBP
required/VBN
to/TO
obtain/VB
sufficient/JJ
statistical/JJ
power/JJR
[/(
3/CD
]/)
./.
====================
Therefore/RB
,/,
there/EX
have/VBP
been/VBN
ongoing/JJ
efforts/NNS
to/TO
increase/VB
the/DT
size/NN
of/IN
study/NN
cohorts/VBZ
./.
====================
One/CD
possible/JJ
way/NN
to/TO
increase/VB
the/DT
sample/NN
size/NN
is/VBZ
to/TO
utilize/VB
publicly/RB
available/JJ
cohorts/NNS
./.
====================
Publicly/RB
available/JJ
control/NN
datasets/NNS
can/MD
be/VB
particularly/RB
useful/JJ
,/,
because/IN
they/PRP
can/MD
be/VB
used/VBN
as/IN
controls/NNS
for/IN
many/JJ
different/JJ
diseases/NNS
./.
====================
One/CD
of/IN
the/DT
popular/JJ
publicly/RB
available/JJ
datasets/NNS
is/VBZ
the/DT
Wellcome/JJ
Trust/NNP
Case/NN
Control/NN
Consortium/NN
(/(
WTCCC/NN
)/)
dataset/NN
[/(
4/CD
]/)
./.
====================
The/DT
WTCCC/NN
study/NN
aimed/VBD
to/TO
identify/VB
associations/NNS
of/IN
genetic/JJ
variations/NNS
with/IN
seven/CD
diseases/NNS
across/IN
the/DT
genome/NN
./.
====================
The/DT
dataset/NN
consists/VBZ
of/IN
the/DT
genotype/NN
data/NNS
of/IN
~2,000/CD
cases/NNS
of/IN
each/DT
of/IN
the/DT
seven/CD
diseases/NNS
and/CC
a/DT
common/JJ
control/NN
set/NN
of/IN
~3,000/CD
individuals/NNS
./.
====================
The/DT
controls/NNS
came/VBD
from/IN
two/CD
sources/NNS
:/:
~1,500/CD
individuals/NNS
from/IN
the/DT
1958/CD
British/JJ
Birth/NN
Cohort/NN
(/(
58C/NN
)/)
and/CC
~1,500/CD
individuals/NNS
selected/VBN
from/IN
blood/NN
donors/NNS
recruited/VBN
as/IN
part/NN
of/IN
the/DT
WTCCC/NN
project/VB
(/(
UK/NN
Blood/NN
Services/NNS
[/(
UKBS/NN
]/)
controls/VBZ
)/)
./.
====================
The/DT
WTCCC/NN
performed/VBN
tests/NNS
to/TO
check/VB
differences/NNS
in/IN
the/DT
allele/NN
frequencies/NNS
of/IN
genome-wide/NN
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
between/IN
the/DT
58C/NN
and/CC
UKBS/NN
groups/NNS
./.
====================
The/DT
results/NNS
indicated/VBD
that/IN
there/EX
were/VBD
no/DT
significant/JJ
differences/NNS
between/IN
the/DT
two/CD
control/JJ
groups/NNS
despite/IN
subtle/JJ
dissimilarities/NNS
in/IN
the/DT
population/NN
groups/NNS
sampled/JJ
,/,
DNA/NN
processing/NN
techniques/NNS
,/,
and/CC
age/NN
./.
====================
More/RBR
recently/RB
,/,
the/DT
analysis/NN
of/IN
human/JJ
leukocyte/NN
antigen/NN
(/(
HLA/NN
)/)
genes/NNS
has/VBZ
become/VBN
widespread/JJ
owing/VBG
to/TO
the/DT
development/NN
of/IN
HLA/NN
imputation/NN
technology/NN
[/(
5-7/CD
]/)
./.
====================
The/DT
HLA/NN
complex/NN
,/,
which/WDT
encodes/VBZ
the/DT
major/JJ
histocompatibility/NN
complex/NN
(/(
MHC/NN
)/)
proteins/NNS
and/CC
is/VBZ
located/JJ
on/IN
chromosome/NN
6/CD
(/(
Chr/NN
./.
====================
6p21.1-6p21.3/CD
)/)
,/,
is/VBZ
the/DT
most/JJS
polymorphic/JJ
and/CC
genetically/RB
variable/JJ
region/NN
in/IN
the/DT
human/JJ
genome/NN
./.
====================
HLA/NN
comprises/VBZ
two/CD
main/JJ
groups/NNS
;/:
class/NN
I/CD
antigens/NNS
(/(
HLA-A/NN
,/,
-B/NN
,/,
and/CC
-C/NN
)/)
and/CC
class/NN
II/CD
antigens/NNS
(/(
HLA-DR/NN
,/,
-DQ/NN
,/,
and/CC
-DP/NN
)/)
which/WDT
form/VBP
key/JJ
determinants/NNS
of/IN
histocompatibility/NN
./.
====================
Large-scale/JJ
HLA/NN
association/NN
analyses/NNS
were/VBD
previously/RB
difficult/JJ
due/JJ
to/TO
the/DT
high/JJ
cost/RB
of/IN
HLA/NN
typing/NN
,/,
but/CC
have/VBP
recently/RB
become/IN
more/RBR
commonly/RB
feasible/JJ
through/IN
the/DT
help/NN
of/IN
HLA/NN
imputation/NN
,/,
which/WDT
can/MD
predict/VB
HLA/NN
information/NN
from/IN
SNP/NN
data/NNS
without/IN
HLA/NN
typing/NN
[/(
6,8/CD
]/)
./.
====================
HLA/NN
association/NN
analysis/NN
is/VBZ
similar/JJ
to/TO
other/JJ
association/NN
analyses/NNS
in/IN
that/DT
a/DT
large/JJ
sample/JJ
size/NN
is/VBZ
critical/JJ
for/IN
the/DT
successful/JJ
mapping/NN
of/IN
variants/NNS
./.
====================
Thus/RB
,/,
the/DT
use/NN
of/IN
publicly/RB
available/JJ
datasets/NNS
such/JJ
as/IN
the/DT
WTCCC/NN
control/NN
dataset/NN
can/MD
also/RB
be/VB
helpful/JJ
in/IN
HLA/NN
analysis/NN
./.
====================
Here/RB
,/,
we/PRP
extend/VBP
the/DT
between-control/NN
homogeneity/NN
analysis/NN
of/IN
the/DT
WTCCC/NN
study/NN
to/TO
HLA/NN
./.
====================
Our/PRP$
goal/NN
was/VBD
to/TO
systematically/RB
examine/VB
potential/JJ
differences/NNS
in/IN
HLA/NN
between/IN
the/DT
58C/NN
and/CC
UKBS/NN
controls/NNS
in/IN
the/DT
WTCCC/NN
dataset/NN
./.
====================
Although/IN
the/DT
WTCCC/NN
project/VB
reported/VBD
that/IN
there/EX
were/VBD
only/RB
few/JJ
differences/NNS
in/IN
the/DT
genome-wide/NN
SNP/NN
frequencies/NNS
between/IN
the/DT
two/CD
control/JJ
groups/NNS
,/,
the/DT
difference/NN
in/IN
HLA/NN
region/NN
has/VBZ
not/RB
been/VBN
examined/VBN
before/IN
./.
====================
If/IN
the/DT
difference/NN
in/IN
HLA/NN
is/VBZ
negligible/JJ
between/IN
the/DT
two/CD
control/JJ
groups/NNS
,/,
this/DT
might/MD
suggest/VBP
that/IN
these/DT
combined/JJ
controls/NNS
can/MD
be/VB
used/VBN
as/IN
additional/JJ
controls/NNS
for/IN
HLA/NN
fine-mapping/VBG
association/NN
studies/NNS
./.
====================
For/IN
this/DT
purpose/NN
,/,
we/PRP
imputed/VBD
HLA/NN
information/NN
for/IN
the/DT
two/CD
control/JJ
datasets/NNS
using/VBG
recently/RB
developed/VBD
HLA/NN
imputation/NN
technology/NN
[/(
5/CD
]/)
with/IN
a/DT
large/JJ
European/JJ
reference/VBP
panel/NN
[/(
9/CD
]/)
./.
====================
The/DT
imputation/NN
yielded/VBD
information/NN
on/IN
HLA/NN
alleles/NNS
,/,
amino/NN
acid/NN
residues/NNS
,/,
and/CC
intragenic/JJ
SNPs/NNS
in/IN
binary/NN
markers/NNS
./.
====================
Then/RB
,/,
we/PRP
tested/VBD
the/DT
significance/NN
of/IN
differences/NNS
in/IN
these/DT
markers/NNS
between/IN
the/DT
control/NN
datasets/NNS
./.
====================
Summary/JJ
of/IN
the/DT
cohorts/NNS
====================
A/DT
detailed/JJ
description/NN
of/IN
the/DT
study/NN
samples/NNS
can/MD
be/VB
found/VBN
in/IN
the/DT
original/JJ
WTCCC/NN
GWAS/NN
paper/NN
[/(
4/CD
]/)
./.
====================
In/IN
summary/NN
,/,
the/DT
WTCCC/NN
dataset/NN
includes/VBZ
cases/NNS
of/IN
seven/CD
major/JJ
complex/NN
diseases/NNS
:/:
type/NN
1/CD
diabetes/VBZ
,/,
type/NN
2/CD
diabetes/NNS
,/,
coronary/JJ
heart/NN
disease/NN
,/,
hypertension/NN
,/,
bipolar/JJ
disorder/NN
,/,
rheumatoid/JJ
arthritis/NN
and/CC
Crohn/NN
disease/NN
,/,
each/DT
with/IN
~2,000/CD
individuals/NNS
,/,
and/CC
~3,000/CD
shared/VBN
controls/NNS
from/IN
two/CD
cohorts/NNS
./.
====================
Among/IN
them/PRP
,/,
we/PRP
only/RB
used/VBN
the/DT
two/CD
control/JJ
cohorts/NNS
./.
====================
The/DT
control/JJ
samples/NNS
were/VBD
derived/VBN
from/IN
two/CD
sources/NNS
:/:
half/PRP
from/IN
the/DT
1958/CD
Birth/NN
Cohort/NN
(/(
58C/NN
)/)
and/CC
the/DT
remainder/NN
from/IN
UKBS/NN
samples/NNS
./.
====================
The/DT
1958/CD
Birth/NN
Cohort/NN
(/(
also/RB
known/VBN
as/IN
the/DT
National/JJ
Child/JJ
Development/NN
Study/NN
)/)
consists/VBZ
of/IN
all/DT
births/NNS
in/IN
England/NN
,/,
Wales/NNS
,/,
and/CC
Scotland/NN
in/IN
1958/CD
./.
====================
The/DT
second/JJ
control/NN
group/NN
consists/VBZ
of/IN
1,500/CD
blood/NN
donors/NNS
recruited/VBN
from/IN
the/DT
UKBS/NN
in/IN
England/NN
,/,
Scotland/NNP
,/,
and/CC
Wales/NNS
./.
====================
SNP/NN
quality/NN
control/NN
and/CC
filtration/NN
====================
In/IN
the/DT
WTCCC/NN
dataset/NN
,/,
4,351/CD
SNPs/NNS
had/VBD
already/RB
been/VBN
excluded/VBN
based/VBN
on/IN
a/DT
Hardy-Weinberg/JJ
equilibrium/NN
(/(
HWE/NNP
)/)
test/VBP
threshold/RB
of/IN
p/NN
</JJR
5.7/CD
×/NNP
10-7/CD
in/IN
the/DT
combined/JJ
set/NN
of/IN
2,938/CD
controls/VBZ
,/,
as/IN
well/RB
as/IN
93/CD
SNPs/NNS
with/IN
p-values/NNS
</JJR
5.7/CD
×/NNP
10-7/CD
from/IN
either/CC
a/DT
one-/CD
or/CC
two-degrees/NNS
of/IN
freedom/JJ
test/NN
for/IN
differences/NNS
between/IN
the/DT
two/CD
control/JJ
groups/NNS
./.
====================
In/IN
this/DT
analysis/NN
,/,
we/PRP
only/RB
focused/VBN
on/IN
autosomal/JJ
variants/NNS
(/(
459,059/CD
SNPs/NNS
)/)
./.
====================
We/PRP
further/RB
performed/VBN
additional/JJ
SNP/NN
quality/NN
control/NN
(/(
QC/NN
)/)
ﬁlters/VBZ
./.
====================
We/PRP
removed/VBD
SNPs/NNS
that/DT
showed/VBD
a/DT
genotype/JJ
failure/NN
rate/NN
greater/JJR
than/IN
0.05/CD
,/,
SNPs/NNS
with/IN
a/DT
minor/JJ
allele/NN
frequency/NN
(/(
MAF/NN
)/)
</JJR
5/CD
%/NN
,/,
and/CC
SNPs/NNS
with/IN
an/DT
HWE/NN
p/NN
</JJR
0.00001/CD
./.
====================
After/IN
applying/VBG
these/DT
QC/NN
criteria/NNS
to/TO
the/DT
combined/JJ
control/NN
cohort/NN
,/,
we/PRP
obtained/VBD
358,085/CD
SNPs/NNS
./.
====================
Principal/JJ
component/NN
analysis/NN
====================
We/PRP
conducted/VBD
principal/JJ
component/NN
analysis/NN
(/(
PCA/NN
)/)
with/IN
PLINK/NN
(/(
v1.90b/NN
)/)
[/(
10/CD
]/)
(/(
--/:
pca/NN
)/)
to/TO
analyze/VB
systematic/JJ
differences/NNS
in/IN
genome-wide/NN
allele/NN
frequencies/NNS
between/IN
the/DT
two/CD
cohorts/NNS
./.
====================
PCA/NN
is/VBZ
a/DT
popular/JJ
dimensionality/NN
reduction/NN
technique/NN
that/DT
can/MD
account/VB
for/IN
population/NN
stratification/NN
in/IN
genetic/JJ
data/NNS
[/(
11/CD
]/)
./.
====================
Prior/JJ
to/TO
applying/VBG
PCA/NN
,/,
we/PRP
used/VBD
PLINK/NN
to/TO
prune/JJ
the/DT
SNP/NN
data/NNS
in/IN
windows/VBZ
of/IN
50/CD
bps/NNS
,/,
removing/VBG
a/DT
SNP/NN
from/IN
each/DT
pair/NN
of/IN
SNPs/NNS
with/IN
an/DT
r2/NN
>/JJR
0.2/CD
./.
====================
A/DT
total/JJ
of/IN
71,083/CD
SNPs/NNS
remained/VBD
after/IN
pruning/VBG
./.
====================
We/PRP
extracted/VBD
the/DT
top/NN
principal/JJ
components/NNS
(/(
PCs/NNS
)/)
that/WDT
explained/VBN
the/DT
most/JJS
variance/RB
in/IN
the/DT
genotype/NN
data/NNS
./.
====================
The/DT
top/NN
two/CD
and/CC
three/CD
PCs/NNS
were/VBD
used/VBN
to/TO
build/JJ
two-/CD
and/CC
three-dimensional/JJ
PC/NN
plots/NNS
./.
====================
The/DT
top/NN
20/CD
components/NNS
were/VBD
used/VBN
as/IN
covariates/VBZ
in/IN
the/DT
logistic/JJ
regression/NN
for/IN
the/DT
genome-wide/NN
SNPs/NNS
,/,
as/IN
well/RB
as/IN
in/IN
the/DT
logistic/JJ
regression/NN
for/IN
the/DT
HLA/NN
binary/NN
markers/NNS
./.
====================
Phase/NN
2/CD
HapMap/NN
dataset/NN
====================
We/PRP
obtained/VBD
the/DT
publicly/RB
available/JJ
Phase/NN
2/CD
HapMap/NN
data/NNS
for/IN
270/CD
individual/JJ
samples/NNS
from/IN
three/CD
different/JJ
populations/NNS
(/(
Central/JJ
European/JJ
[/(
CEU/NN
]/)
,/,
Yoruba/NN
in/IN
Ibadan/JJ
,/,
Nigeria/NNP
[/(
YRI/NN
]/)
,/,
and/CC
the/DT
East/JJ
Asian/JJ
combined/JJ
sample/JJ
of/IN
Japanese/JJ
in/IN
Tokyo/JJ
and/CC
Han/JJ
Chinese/JJ
in/IN
Beijing/VBG
[/(
Asian/JJ
:/:
JPT/NN
+/CC
CHB/NN
]/)
)/)
[/(
12/CD
]/)
./.
====================
We/PRP
used/VBD
this/DT
dataset/NN
to/TO
perform/VB
PCA/NN
to/TO
quantify/VB
the/DT
population/NN
structure/NN
of/IN
the/DT
samples/NNS
./.
====================
Kolmogorov-Smirnov/NN
test/NN
====================
The/DT
Kolmogorov-Smirnov/NN
(/(
K-S/NNS
)/)
test/NN
was/VBD
used/VBN
to/TO
assess/VB
the/DT
equality/NN
of/IN
frequency/NN
distributions/NNS
between/IN
the/DT
58C/NN
and/CC
UKBS/NN
cohorts/NNS
./.
====================
We/PRP
calculated/VBD
the/DT
corresponding/JJ
D/NN
statistic/JJ
and/CC
p-value/JJ
of/IN
the/DT
test/NN
using/VBG
the/DT
basic/JJ
stats/NNS
package/NN
in/IN
R./NNP
p-values/NNS
were/VBD
two-sided/VBN
./.
====================
Imputation/NN
of/IN
HLA/NN
alleles/NNS
====================
We/PRP
used/VBD
SNP2HLA/NN
[/(
5/CD
]/)
to/TO
impute/VB
HLA/NN
information/NN
for/IN
the/DT
58C/NN
and/CC
UKBS/NN
cohorts/NNS
,/,
where/WRB
the/DT
HLA/NN
information/NN
was/VBD
generated/VBN
as/IN
binary/RB
markers/NNS
for/IN
(/(
1/CD
)/)
HLA/NN
alleles/NNS
,/,
(/(
2/CD
)/)
amino/NN
acid/NN
residues/NNS
,/,
and/CC
(/(
3/CD
)/)
intragenic/JJ
SNPs/NNS
./.
====================
For/IN
the/DT
reference/NN
panel/NN
for/IN
imputation/NN
,/,
we/PRP
employed/VBD
the/DT
Type/NN
I/CD
Diabetes/NNS
Genetics/NNS
Consortium/NN
dataset/NN
,/,
which/WDT
consists/VBZ
of/IN
5,225/CD
individuals/NNS
of/IN
European/JJ
ancestry/NN
[/(
9/CD
]/)
./.
====================
The/DT
genomic/JJ
region/NN
was/VBD
restricted/JJ
to/TO
the/DT
MHC/NN
complex/NN
region/NN
(/(
chr6:29-34Mb/NN
,/,
hg18/NN
)/)
on/IN
chromosome/NN
6/CD
before/IN
imputation/NN
./.
====================
As/IN
a/DT
result/JJ
,/,
we/PRP
obtained/VBD
the/DT
imputed/JJ
genotypes/NNS
of/IN
8,961/CD
binary/RB
markers/NNS
,/,
which/WDT
were/VBD
composed/VBN
of/IN
424/CD
markers/NNS
for/IN
HLA/NN
alleles/NNS
(/(
e.g./FW
,/,
HLA_A_0101/NNP
;/:
the/DT
presence/NN
of/IN
HLA-A*01:01/NN
allele/NN
in/IN
the/DT
HLA-A/NN
gene/NN
)/)
,/,
1,276/CD
markers/NNS
for/IN
amino/NN
acid/NN
residues/NNS
(/(
e.g./FW
,/,
AA_A_245_30020064_V/NNP
;/:
the/DT
presence/NN
of/IN
valine/NN
at/IN
the/DT
245th/JJ
amino/NN
acid/NN
position/NN
of/IN
the/DT
HLA-A/NN
gene/NN
)/)
,/,
1,390/CD
markers/NNS
for/IN
intragenic/JJ
SNPs/NNS
(/(
e.g./FW
,/,
SNP_A_30020064/NN
;/:
the/DT
intragenic/JJ
SNP/NN
at/IN
base/NN
position/NN
of/IN
30020064/CD
in/IN
the/DT
HLA-A/NN
gene/NN
)/)
,/,
and/CC
5,871/CD
markers/NNS
for/IN
genomic/JJ
variants/NNS
(/(
e.g./FW
,/,
rs969931/RB
)/)
./.
====================
Allele/DT
frequency/NN
difference/NN
analysis/NN
between/IN
the/DT
two/CD
control/JJ
cohorts/NNS
====================
We/PRP
performed/VBD
association/NN
tests/NNS
to/TO
compare/VB
allele/NN
frequencies/NNS
between/IN
the/DT
control/NN
cohorts/NNS
./.
====================
We/PRP
used/VBD
the/DT
logistic/JJ
regression/NN
model/NN
in/IN
PLINK/NN
v.1.90b/NN
(/(
--/:
logistic/JJ
)/)
[/(
10/CD
]/)
./.
====================
To/TO
set/VB
the/DT
phenotypes/NNS
,/,
the/DT
UKBS/NN
cohort/NN
was/VBD
set/NN
as/IN
“/CD
control/NN
”/CD
and/CC
the/DT
58C/NN
cohort/NN
as/IN
“/CD
case./FW
”/CD
We/PRP
first/RB
conducted/VBN
two-cohort/JJ
association/NN
tests/NNS
for/IN
genome-wide/NN
SNPs/NNS
across/IN
the/DT
genome/NN
./.
====================
Since/IN
we/PRP
did/VBD
not/RB
have/VB
regional/JJ
information/NN
on/IN
the/DT
samples/NNS
,/,
which/WDT
was/VBD
used/VBN
in/IN
similar/JJ
analyses/NNS
in/IN
the/DT
WTCCC/NN
study/NN
,/,
we/PRP
controlled/VBD
for/IN
possible/JJ
population/NN
stratification/NN
by/IN
including/VBG
the/DT
top/NN
20/CD
PCs/NNS
as/IN
additional/JJ
covariates/NNS
./.
====================
For/IN
the/DT
HLA/NN
analysis/NN
,/,
we/PRP
tested/VBD
all/DT
imputed/JJ
markers/NNS
,/,
including/VBG
HLA/NN
alleles/NNS
,/,
amino/NN
acids/NNS
,/,
and/CC
SNPs/NNS
in/IN
the/DT
MHC/NN
region/NN
./.
====================
Similar/JJ
to/TO
the/DT
genome/NN
analysis/NN
,/,
we/PRP
included/VBD
the/DT
same/JJ
top/NN
20/CD
PCs/NNS
as/IN
covariates/VBZ
in/IN
the/DT
HLA/NN
analysis/NN
./.
====================
Principal/JJ
component/NN
analysis/NN
====================
We/PRP
first/RB
used/VBN
PCA/NN
to/TO
analyze/VB
differences/NNS
between/IN
the/DT
two/CD
control/JJ
cohorts/NNS
at/IN
the/DT
population/NN
level/NN
./.
====================
We/PRP
calculated/VBD
PCs/NNS
in/IN
four/CD
ways/NNS
:/:
(/(
1/CD
)/)
using/VBG
the/DT
58C/NN
cohort/JJ
only/RB
,/,
(/(
2/CD
)/)
using/VBG
the/DT
UKBS/NN
cohort/JJ
only/RB
,/,
(/(
3/CD
)/)
using/VBG
the/DT
two/CD
cohorts/NNS
combined/JJ
,/,
and/CC
(/(
4/CD
)/)
using/VBG
the/DT
combined/JJ
set/NN
with/IN
the/DT
HapMap/NN
data/NNS
(/(
N=270/CD
)/)
integrated/VBN
./.
====================
We/PRP
applied/VBD
SNP/NN
QC/NN
filters/NNS
before/IN
PCA/NN
(/(
see/VB
Methods/NNS
)/)
./.
====================
PCs/NNS
were/VBD
calculated/VBN
based/VBN
on/IN
the/DT
variance-standardized/VBN
relationship/NN
matrix/NN
among/IN
the/DT
individuals/NNS
included/VBD
in/IN
each/DT
analysis/NN
./.
====================
Fig/NN
./.
====================
1A/NN
and/CC
1B/NN
show/VBP
the/DT
PCs/NNS
in/IN
the/DT
58C/NN
and/CC
UKBS/NN
cohorts/NNS
,/,
respectively/RB
,/,
and/CC
Fig/NN
./.
====================
1C/NN
shows/VBZ
the/DT
results/NNS
when/WRB
the/DT
two/CD
cohorts/NNS
were/VBD
merged/VBN
./.
====================
Fig/NN
./.
====================
1C/NN
demonstrates/VBZ
high/JJ
similarity/NN
in/IN
the/DT
ranges/NNS
of/IN
the/DT
first/JJ
two/CD
PCs/NNS
between/IN
the/DT
two/CD
cohorts/NNS
,/,
except/IN
for/IN
two/CD
outliers/NNS
(/(
one/CD
in/IN
each/DT
cohort/NN
)/)
at/IN
the/DT
bottom/CC
right/JJ
corner/NN
of/IN
the/DT
plot/NN
./.
====================
Fig/NN
./.
====================
1D/CD
is/VBZ
a/DT
tridimensional/JJ
plot/NN
of/IN
the/DT
PCs/NNS
of/IN
the/DT
two/CD
control/JJ
cohorts/NNS
./.
====================
The/DT
red/JJ
sphere/NN
corresponds/VBZ
to/TO
the/DT
58C/NN
group/NN
,/,
and/CC
the/DT
blue/JJ
indicates/VBZ
the/DT
UKBS/NN
group/NN
./.
====================
In/IN
the/DT
3-PC/NN
plot/NN
,/,
similar/JJ
to/TO
the/DT
2-PC/NN
plot/NN
,/,
the/DT
two/CD
cohorts/NNS
were/VBD
not/RB
visually/RB
distinct/JJ
from/IN
each/DT
other/JJ
./.
====================
Fig/NN
./.
====================
1E/NN
presents/VBZ
the/DT
PCs/NNS
of/IN
the/DT
WTCCC/NN
merged/JJ
with/IN
three/CD
HapMap/NN
populations/NNS
(/(
CEU/NN
,/,
YRI/NN
,/,
and/CC
Asian/JJ
[/(
CHB/NN
,/,
JPT/NN
]/)
)/)
./.
====================
The/DT
plot/NN
shows/VBZ
that/IN
the/DT
58C/NN
,/,
UKBS/NN
,/,
and/CC
CEU/NN
cohorts/NNS
were/VBD
grouped/VBN
together/RB
in/IN
the/DT
PC/NN
plot/NN
,/,
showing/VBG
that/IN
the/DT
two/CD
control/JJ
cohorts/NNS
had/VBD
European/JJ
ancestry/NN
homogeneous/JJ
to/TO
the/DT
CEU/NN
./.
====================
SNP/NN
allele/NN
frequency/NN
distribution/NN
of/IN
the/DT
two/CD
cohorts/NNS
====================
We/PRP
examined/VBD
the/DT
allele/NN
frequencies/NNS
of/IN
genome-wide/NN
SNPs/NNS
in/IN
the/DT
two/CD
cohorts/NNS
,/,
using/VBG
358,085/CD
autosomal/JJ
SNPs/NNS
from/IN
2,938/CD
samples/NNS
(/(
total/JJ
genotyping/VBG
rate/NN
,/,
0.996/CD
)/)
./.
====================
Table/JJ
1/CD
provides/VBZ
descriptive/JJ
statistics/NNS
of/IN
the/DT
allele/NN
frequency/NN
distribution/NN
in/IN
each/DT
cohort/NN
./.
====================
These/DT
statistics/NNS
did/VBD
not/RB
show/VB
any/DT
distinctive/JJ
differences/NNS
between/IN
the/DT
two/CD
cohorts/NNS
./.
====================
In/IN
addition/NN
,/,
Fig/NN
./.
====================
2A/NN
and/CC
2B/NN
show/VBP
the/DT
patterns/NNS
of/IN
the/DT
MAF/NN
differences/NNS
./.
====================
We/PRP
performed/VBD
the/DT
K-S/NN
test/NN
,/,
a/DT
general/JJ
nonparametric/JJ
method/NN
for/IN
comparing/VBG
the/DT
density/NN
distributions/NNS
of/IN
two/CD
datasets/NNS
./.
====================
Fig/NN
./.
====================
2C/NN
shows/VBZ
a/DT
plot/NN
of/IN
the/DT
empirical/JJ
cumulative/JJ
density/NN
function/NN
(/(
ECDF/NN
)/)
curves/VBZ
of/IN
the/DT
two/CD
cohorts/NNS
./.
====================
The/DT
K-S/NN
test/NN
returns/VBZ
a/DT
D/NN
statistic/JJ
,/,
which/WDT
refers/VBZ
to/TO
the/DT
absolute/JJ
maximum/NN
distance/NN
between/IN
the/DT
ECDF/NN
of/IN
the/DT
two/CD
samples/NNS
and/CC
a/DT
p-value/JJ
corresponding/VBG
to/TO
the/DT
D/NN
statistic/JJ
./.
====================
D/NN
was/VBD
0.015/CD
and/CC
the/DT
p-value/JJ
was/VBD
0.819/CD
;/:
therefore/RB
,/,
we/PRP
could/MD
not/RB
reject/VB
the/DT
null/JJ
hypothesis/NN
that/IN
the/DT
two/CD
datasets/NNS
were/VBD
drawn/VBN
from/IN
the/DT
same/JJ
distribution/NN
./.
====================
Allele/DT
frequency/NN
association/NN
test/NN
between/IN
the/DT
two/CD
cohorts/NNS
====================
Next/RB
,/,
we/PRP
performed/VBD
a/DT
GWAS/JJ
to/TO
detect/VB
genomic/JJ
variants/NNS
that/WDT
showed/VBD
significant/JJ
differences/NNS
in/IN
the/DT
MAF/NN
between/IN
the/DT
two/CD
cohorts/NNS
./.
====================
In/IN
the/DT
original/JJ
study/NN
,/,
the/DT
WTCCC/NN
performed/VBN
a/DT
similar/JJ
test/NN
to/TO
check/VB
differences/NNS
in/IN
the/DT
allele/NN
frequencies/NNS
between/IN
the/DT
58C/NN
and/CC
UKBS/NN
cohorts/NNS
using/VBG
genome-wide/JJ
scans/NNS
./.
====================
In/IN
that/DT
analysis/NN
,/,
they/PRP
stratified/VBD
the/DT
samples/NNS
based/VBN
on/IN
their/PRP$
broad/JJ
geographical/JJ
origin/NN
(/(
12/CD
UK/NN
regions/NNS
)/)
./.
====================
The/DT
result/NN
of/IN
the/DT
test/NN
statistics/NNS
in/IN
a/DT
quantile-quantile/JJ
(/(
Q-Q/NN
)/)
plot/NN
indicated/VBD
that/IN
there/EX
were/VBD
no/DT
significant/JJ
differences/NNS
between/IN
the/DT
two/CD
control/JJ
groups/NNS
./.
====================
They/PRP
showed/VBD
that/IN
their/PRP$
samples/NNS
did/VBD
not/RB
show/VB
a/DT
clear/JJ
population/NN
structure/NN
in/IN
multidimensional/JJ
scaling/VBG
and/CC
PCA/NN
plots/NNS
,/,
despite/IN
the/DT
12/CD
different/JJ
origins/NNS
of/IN
the/DT
samples/NNS
./.
====================
Our/PRP$
association/NN
analysis/NN
was/VBD
similar/JJ
to/TO
the/DT
analysis/NN
in/IN
the/DT
original/JJ
paper/NN
,/,
but/CC
different/JJ
in/IN
that/DT
we/PRP
included/VBD
the/DT
top/NN
20/CD
PCs/NNS
as/IN
covariates/VBZ
instead/RB
of/IN
performing/VBG
a/DT
stratified/JJ
analysis/NN
based/VBN
on/IN
12/CD
geographical/JJ
regions/NNS
./.
====================
The/DT
reason/NN
for/IN
this/DT
difference/NN
is/VBZ
that/DT
the/DT
geographical/JJ
origin/NN
information/NN
was/VBD
not/RB
readily/RB
available/JJ
for/IN
download/JJ
from/IN
the/DT
WTCCC/NN
website/JJ
./.
====================
To/TO
our/PRP$
knowledge/NN
,/,
only/RB
the/DT
genotype/NN
data/NNS
and/CC
the/DT
disease/NN
status/NN
were/VBD
publicly/RB
available/JJ
to/TO
researchers/NNS
./.
====================
Thus/RB
,/,
in/IN
general/JJ
,/,
a/DT
researcher/JJ
using/VBG
the/DT
WTCCC/NN
controls/NNS
would/MD
likely/JJ
use/NN
only/RB
PCs/NNS
as/IN
covariates/VBZ
instead/RB
of/IN
geographical/JJ
information/NN
./.
====================
Moreover/RB
,/,
even/RB
if/IN
a/DT
researcher/JJ
were/VBD
to/TO
obtain/VB
the/DT
geographical/JJ
region/NN
information/NN
for/IN
the/DT
WTCCC/NN
controls/NNS
,/,
it/PRP
would/MD
not/RB
possible/JJ
to/TO
use/VB
this/DT
information/NN
as/IN
a/DT
covariate/JJ
in/IN
the/DT
case/control/JJ
analysis/NN
without/IN
having/VBG
the/DT
same/JJ
information/NN
for/IN
cases/NNS
./.
====================
Therefore/RB
,/,
it/PRP
is/VBZ
worthwhile/JJ
to/TO
examine/VB
the/DT
differences/NNS
between/IN
the/DT
two/CD
control/JJ
cohorts/NNS
in/IN
an/DT
analysis/NN
using/VBG
only/RB
PCs/NNS
as/IN
covariates/VBZ
./.
====================
Specifically/RB
,/,
we/PRP
tested/VBD
the/DT
MAF/NN
difference/NN
between/IN
the/DT
two/CD
cohorts/NNS
using/VBG
logistic/JJ
regression/NN
,/,
while/IN
including/VBG
the/DT
top/NN
20/CD
PCs/NNS
as/IN
covariates/VBZ
to/TO
account/VB
for/IN
regional/JJ
differences/NNS
in/IN
the/DT
samples/NNS
./.
====================
To/TO
this/DT
end/NN
,/,
we/PRP
set/VBP
one/CD
cohort/NN
as/IN
cases/NNS
(/(
58C/NN
)/)
and/CC
another/DT
cohort/NN
as/IN
controls/NNS
(/(
UKBS/NN
)/)
./.
====================
We/PRP
then/RB
performed/VBN
association/NN
tests/NNS
to/TO
identify/VB
the/DT
associations/NNS
between/IN
SNPs/NNS
and/CC
the/DT
cohort/NN
identifier/JJR
./.
====================
Fig/NN
./.
====================
3A/NN
shows/VBZ
the/DT
Manhattan/JJ
plot/NN
of/IN
associations/NNS
./.
====================
We/PRP
did/VBD
not/RB
find/VB
any/DT
loci/NNS
that/IN
exceeded/VBD
the/DT
threshold/JJ
for/IN
genome-wide/NN
significance/NN
of/IN
5.7/CD
×/CD
10-7/CD
(/(
red/JJ
line/NN
)/)
,/,
which/WDT
was/VBD
the/DT
threshold/JJ
used/VBN
in/IN
the/DT
WTCCC/NN
study/NN
./.
====================
This/DT
is/VBZ
unsurprising/JJ
because/IN
the/DT
dataset/NN
we/PRP
used/VBD
was/VBD
already/RB
filtered/VBN
to/TO
remove/VB
any/DT
SNPs/NNS
with/IN
p/NN
</JJR
5.7/CD
×/CD
10-7/CD
in/IN
the/DT
MAF/NN
difference/NN
test/NN
of/IN
the/DT
original/JJ
study/NN
./.
====================
However/RB
,/,
we/PRP
could/MD
find/VB
several/JJ
loci/NNS
with/IN
moderate/JJ
significance/NN
(/(
p/NN
</JJR
1/CD
×/NN
10-5/CD
,/,
blue/JJ
line/NN
)/)
./.
====================
Fig/NN
./.
====================
3B/NN
demonstrates/VBZ
that/IN
the/DT
association/NN
tests/NNS
had/VBD
slight/JJ
inflation/NN
(/(
genomic/JJ
control/NN
inflation/NN
factor/NN
[/(
λ/JJ
]/)
:/:
1.04/CD
)/)
./.
====================
Upon/IN
visual/JJ
inspection/NN
,/,
the/DT
Q-Q/NN
plot/NN
appeared/VBD
slightly/RB
more/RBR
inflated/JJ
in/IN
our/PRP$
analysis/NN
than/IN
the/DT
Q-Q/NN
plot/NN
presented/VBN
in/IN
the/DT
original/JJ
paper/NN
(/(
Fig/NN
./.
====================
3B/NN
of/IN
the/DT
WTCCC/NN
study/NN
[/(
4/CD
]/)
)/)
,/,
possibly/RB
because/IN
the/DT
exact/JJ
regional/JJ
information/NN
was/VBD
not/RB
included/VBN
in/IN
the/DT
analysis/NN
./.
====================
An/DT
exact/JJ
comparison/NN
of/IN
inflation/NN
was/VBD
not/RB
possible/JJ
because/IN
the/DT
result/NN
of/IN
the/DT
inflation/NN
statistic/JJ
in/IN
the/DT
original/JJ
study/NN
was/VBD
not/RB
available/JJ
./.
====================
HLA/NN
allele/NN
frequency/NN
distribution/NN
of/IN
the/DT
two/CD
cohorts/NNS
====================
Next/RB
,/,
we/PRP
examined/VBD
the/DT
HLA/NN
allele/NN
frequencies/NNS
in/IN
each/DT
cohort/NN
./.
====================
We/PRP
imputed/VBD
the/DT
HLA/NN
information/NN
using/VBG
SNP2HLA/NN
./.
====================
The/DT
imputation/NN
gave/VBD
us/PRP
binary/NN
markers/NNS
for/IN
(/(
1/CD
)/)
HLA/NN
alleles/NNS
,/,
(/(
2/CD
)/)
amino/NN
acid/NN
residues/NNS
,/,
and/CC
(/(
3/CD
)/)
intragenic/JJ
SNPs/NNS
./.
====================
Using/VBG
imputed/JJ
binary/NN
markers/NNS
,/,
we/PRP
extracted/VBD
two-digit/JJ
and/CC
four-digit/VBD
HLA/NN
alleles/NNS
for/IN
each/DT
sample/NN
./.
====================
As/IN
a/DT
result/NN
,/,
we/PRP
obtained/VBD
a/DT
total/JJ
of/IN
23,504/CD
imputed/JJ
alleles/NNS
for/IN
eight/CD
genes/NNS
in/IN
2,938/CD
samples/NNS
./.
====================
We/PRP
focused/VBD
on/IN
the/DT
two-digit/JJ
alleles/NNS
in/IN
this/DT
analysis/NN
./.
====================
When/WRB
we/PRP
counted/VBD
the/DT
number/NN
of/IN
unique/JJ
two-digit/RB
alleles/NNS
in/IN
each/DT
gene/NN
,/,
we/PRP
found/VBD
18/CD
alleles/NNS
for/IN
HLA-A/NN
,/,
27/CD
alleles/NNS
for/IN
HLA-B/NN
,/,
13/CD
alleles/NNS
for/IN
HLA-C/NN
,/,
three/CD
alleles/NNS
for/IN
HLA-DPA1/NN
,/,
17/CD
alleles/NNS
for/IN
HLA-DPB1/NN
,/,
six/CD
alleles/NNS
for/IN
HLA-DQA1/NN
,/,
five/CD
alleles/NNS
for/IN
HLA-DQB1/NN
,/,
and/CC
13/CD
alleles/NNS
for/IN
HLA-DRB1/NN
./.
====================
Most/JJS
of/IN
the/DT
alleles/NNS
(/(
97/CD
)/)
were/VBD
observed/VBN
in/IN
both/DT
cohorts/NNS
,/,
and/CC
five/CD
alleles/NNS
were/VBD
detected/VBN
in/IN
a/DT
single/JJ
cohort/NN
(/(
two/CD
alleles/NNS
for/IN
58C/NN
and/CC
three/CD
alleles/NNS
for/IN
UKBS/NN
)/)
./.
====================
The/DT
two-digit/JJ
HLA/NN
allele/NN
frequencies/NNS
are/VBP
listed/VBN
in/IN
Supplementary/JJ
Table/JJ
1/CD
./.
====================
Table/JJ
2/CD
provides/VBZ
the/DT
descriptive/JJ
statistics/NNS
of/IN
the/DT
two-digit/JJ
HLA/NN
allele/NN
frequency/NN
distribution/NN
in/IN
each/DT
cohort/NN
./.
====================
These/DT
statistics/NNS
did/VBD
not/RB
show/VB
distinctive/JJ
differences/NNS
between/IN
the/DT
two/CD
cohorts/NNS
./.
====================
The/DT
mean/JJ
absolute/JJ
difference/NN
in/IN
the/DT
HLA/NN
allele/NN
frequencies/NNS
was/VBD
0.00562/CD
./.
====================
Fig/NN
./.
====================
4A/CD
and/CC
4B/NN
show/VBP
the/DT
patterns/NNS
of/IN
the/DT
HLA/NN
allele/NN
frequency/NN
differences/NNS
./.
====================
We/PRP
then/RB
performed/VBN
the/DT
K-S/NN
test/NN
for/IN
each/DT
HLA/NN
gene/NN
,/,
and/CC
the/DT
results/NNS
are/VBP
presented/VBN
in/IN
Fig/NN
./.
====================
4C/NN
./.
====================
All/DT
the/DT
HLA/NN
genes/NNS
showed/VBD
non-significant/JJ
p-values/NNS
in/IN
the/DT
K-S/NN
test/NN
,/,
demonstrating/VBG
that/IN
there/EX
was/VBD
no/DT
significant/JJ
difference/NN
in/IN
the/DT
imputed/JJ
HLA/NN
allele/NN
frequencies/NNS
between/IN
the/DT
two/CD
control/JJ
cohorts/NNS
./.
====================
HLA/NN
association/NN
test/NN
between/IN
the/DT
two/CD
cohorts/NNS
====================
Finally/RB
,/,
we/PRP
tested/VBD
the/DT
HLA/NN
difference/NN
between/IN
the/DT
two/CD
cohorts/NNS
using/VBG
logistic/JJ
regression/NN
./.
====================
Similar/JJ
to/TO
the/DT
genome-wide/NN
analysis/NN
above/IN
,/,
we/PRP
included/VBD
the/DT
top/NN
20/CD
PCs/NNS
as/IN
covariates/VBZ
to/TO
account/VB
for/IN
regional/JJ
differences/NNS
among/IN
the/DT
samples/NNS
./.
====================
Again/RB
,/,
we/PRP
set/VBP
one/CD
cohort/NN
as/IN
cases/NNS
(/(
58C/NN
)/)
and/CC
the/DT
other/JJ
cohort/JJ
as/IN
controls/NNS
(/(
UKBS/NN
)/)
./.
====================
We/PRP
then/RB
performed/VBN
association/NN
tests/NNS
to/TO
identify/VB
associations/NNS
between/IN
markers/NNS
in/IN
the/DT
MHC/NN
region/NN
(/(
including/VBG
both/CC
the/DT
imputed/JJ
binary/NN
markers/NNS
and/CC
the/DT
genotyped/VBN
SNPs/NNS
)/)
and/CC
the/DT
cohort/NN
identifier/RBR
./.
====================
Fig/NN
./.
====================
5A/CD
shows/VBZ
the/DT
Manhattan/JJ
plot/NN
of/IN
associations/NNS
./.
====================
We/PRP
did/VBD
not/RB
find/VB
any/DT
binary/JJ
marker/NN
that/DT
exceeded/VBD
the/DT
threshold/JJ
for/IN
genome-wide/NN
significance/NN
of/IN
5.7/CD
×/CD
10-7/CD
(/(
red/JJ
line/NN
)/)
,/,
which/WDT
was/VBD
the/DT
threshold/JJ
used/VBN
in/IN
the/DT
WTCCC/NN
study/NN
./.
====================
Fig/NN
./.
====================
5B/NN
demonstrates/VBZ
that/IN
the/DT
association/NN
tests/NNS
did/VBD
not/RB
show/VB
inflation/NN
(/(
λ/LS
=/JJ
0.92/CD
for/IN
all/DT
markers/NNS
and/CC
λ/FW
=/JJ
0.93/CD
for/IN
markers/NNS
with/IN
a/DT
frequency/NN
≥/CD
0.05/CD
)/)
./.
====================
Overall/RB
,/,
both/CC
the/DT
Manhattan/JJ
plot/NN
and/CC
the/DT
Q-Q/NN
plot/NN
showed/VBD
that/IN
there/EX
was/VBD
no/DT
significant/JJ
difference/NN
in/IN
HLA/NN
between/IN
the/DT
two/CD
control/JJ
cohorts/NNS
,/,
emphasizing/VBG
that/DT
the/DT
two/CD
control/JJ
cohorts/NNS
can/MD
be/VB
used/VBN
as/IN
a/DT
single/JJ
combined/JJ
control/NN
for/IN
HLA/NN
analyses/NNS
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
compared/VBD
the/DT
two/CD
control/JJ
cohorts/NNS
of/IN
the/DT
WTCCC/NN
dataset/NN
(/(
UKBS/NN
and/CC
58C/NN
)/)
./.
====================
We/PRP
focused/VBD
on/IN
between-cohort/NN
differences/NNS
in/IN
the/DT
HLA/NN
genes/NNS
,/,
which/WDT
belong/VBP
to/TO
the/DT
polymorphic/JJ
region/NN
of/IN
chromosome/NN
6/CD
./.
====================
In/IN
both/DT
the/DT
association/NN
analysis/NN
of/IN
the/DT
genome-wide/NN
SNPs/NNS
and/CC
the/DT
association/NN
analysis/NN
of/IN
the/DT
imputed/JJ
HLA/NN
markers/NNS
,/,
no/DT
alleles/NNS
showed/VBD
a/DT
significant/JJ
difference/NN
in/IN
allele/NN
frequency/NN
between/IN
the/DT
cohorts/NNS
./.
====================
Furthermore/RB
,/,
in/IN
the/DT
K-S/NN
test/NN
,/,
the/DT
two/CD
cohorts/NNS
did/VBD
not/RB
show/VB
statistically/RB
significant/JJ
differences/NNS
in/IN
any/DT
HLA/NN
gene/NN
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
the/DT
two/CD
control/JJ
cohorts/NNS
are/VBP
genetically/RB
homogeneous/JJ
in/IN
HLA/NN
,/,
and/CC
that/IN
the/DT
combined/JJ
controls/NNS
of/IN
the/DT
WTCCC/NN
can/MD
be/VB
used/VBN
as/IN
supplementary/JJ
controls/NNS
for/IN
HLA/NN
fine-mapping/VBG
studies/NNS
as/IN
well/RB
,/,
as/IN
for/IN
GWAS/NN
./.
====================
However/RB
,/,
we/PRP
note/VBP
that/IN
researchers/NNS
must/MD
evaluate/VB
homogeneity/NN
between/IN
their/PRP$
own/JJ
control/NN
cohort/NN
and/CC
the/DT
combined/JJ
WTCCC/NN
controls/NNS
if/IN
they/PRP
are/VBP
to/TO
use/VB
the/DT
WTCCC/NN
data/NNS
as/IN
additional/JJ
controls/NNS
,/,
because/IN
we/PRP
only/RB
evaluated/VBD
the/DT
homogeneity/NN
between/IN
the/DT
two/CD
WTCCC/NN
control/NN
datasets/NNS
themselves/DT
./.
====================
Principal/JJ
component/NN
(/(
PC/NN
)/)
analysis/NN
of/IN
genotypic/JJ
frequencies/NNS
of/IN
genome-wide/NN
single-nucleotide/JJ
polymorphism/NN
markers/NNS
./.
====================
(/(
A/NN
)/)
The/DT
first/JJ
two/CD
PCs/NNS
for/IN
58C/NN
individuals/NNS
./.
====================
(/(
B/NN
)/)
The/DT
first/JJ
two/CD
PCs/NNS
for/IN
UK/NN
Blood/NN
Services/NNS
(/(
UKBS/NN
)/)
individuals/NNS
./.
====================
(/(
C/NN
)/)
The/DT
first/JJ
two/CD
PCs/NNS
for/IN
58C/NN
and/CC
UKBS/NN
individuals/NNS
./.
====================
(/(
D/NN
)/)
The/DT
first/JJ
three/CD
PCs/NNS
for/IN
58C/NN
and/CC
UKBS/NN
individuals/NNS
./.
====================
(/(
E/NN
)/)
The/DT
first/JJ
two/CD
PCs/NNS
for/IN
58C/NN
and/CC
UKBS/NN
individuals/NNS
integrated/VBN
with/IN
the/DT
HapMap/NN
populations/NNS
(/(
Phase2/NN
)/)
./.
====================
Comparison/NN
of/IN
single-nucleotide/JJ
polymorphism/NN
minor/JJ
allele/NN
frequency/NN
(/(
MAF/NN
)/)
between/IN
the/DT
two/CD
cohorts/NNS
./.
====================
(/(
A/NN
)/)
MAF/NN
comparison/NN
of/IN
the/DT
two/CD
cohorts/NNS
./.
====================
(/(
B/NN
)/)
Density/NN
plot/NN
of/IN
the/DT
absolute/JJ
MAF/NN
difference/NN
of/IN
the/DT
two/CD
cohorts/NNS
./.
====================
(/(
C/NN
)/)
ECDF/NN
curve/NN
plot/NN
for/IN
the/DT
Kolmogorov-Smirnov/NN
test/NN
./.
====================
UKBS/NN
,/,
UK/NN
Blood/NN
Services/NNS
./.
====================
Genome-wide/NN
association/NN
results/NNS
and/CC
quantile-quantile/JJ
(/(
Q-Q/NN
)/)
plots/NNS
for/IN
genome-wide/NN
association/NN
study/NN
p-values/VBZ
./.
====================
(/(
A/NN
)/)
Manhattan/JJ
plot/NN
of/IN
genome-wide/NN
association/NN
results/NNS
./.
====================
Within/IN
each/DT
chromosome/NN
position/NN
shown/VBN
on/IN
the/DT
x/NN
axis/NN
,/,
log10/NN
(/(
p-values/NNS
)/)
of/IN
the/DT
association/NN
statistics/NNS
are/VBP
visualized/VBN
on/IN
the/DT
y-axis/NN
./.
====================
The/DT
red/JJ
line/NN
denotes/VBZ
genome-wide/NN
significance/NN
(/(
5.7/CD
×/CD
10-7/CD
)/)
./.
====================
(/(
B/NN
)/)
Q-Q/NN
plot/NN
of/IN
association/NN
p-values/NNS
./.
====================
Red/VBN
line/NN
denotes/VBZ
the/DT
expected/VBN
values/NNS
under/IN
no/DT
inflation/NN
./.
====================
Comparison/NN
of/IN
human/JJ
leukocyte/NN
antigen/NN
(/(
HLA/NN
)/)
allele/NN
frequency/NN
between/IN
the/DT
two/CD
cohorts/NNS
./.
====================
(/(
A/NN
)/)
HLA/NN
allele/NN
frequency/NN
comparison/NN
of/IN
the/DT
two/CD
cohorts/NNS
./.
====================
(/(
B/NN
)/)
Density/NN
plot/NN
of/IN
the/DT
absolute/JJ
HLA/NN
allele/NN
frequency/NN
difference/NN
of/IN
the/DT
two/CD
cohorts/NNS
./.
====================
(/(
C/NN
)/)
p-value/NN
of/IN
the/DT
Kolmogorov-Smirnov/NN
test/NN
in/IN
each/DT
of/IN
the/DT
HLA/NN
genes/NNS
./.
====================
UKBS/NN
,/,
UK/NN
Blood/NN
Services/NNS
;/:
AF/NN
,/,
allele/NN
frequencies/NNS
./.
====================
Imputed/JJ
human/JJ
leukocyte/NN
antigen/NN
(/(
HLA/NN
)/)
-wide/NN
association/NN
results/NNS
and/CC
quantile-quantile/JJ
(/(
Q-Q/NN
)/)
plots/NNS
for/IN
p-values/NNS
./.
====================
(/(
A/NN
)/)
Manhattan/JJ
plot/NN
of/IN
MHC/NN
complex/NN
region-wide/NN
association/NN
results/NNS
./.
====================
The/DT
p-values/NNS
are/VBP
from/IN
the/DT
binary/NN
markers/NNS
for/IN
imputed/JJ
HLA/NN
alleles/NNS
(/(
yellow/RB
)/)
,/,
amino/NN
acid/NN
residues/NNS
(/(
red/JJ
)/)
,/,
genotyped/VBD
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
(/(
gray/NN
)/)
and/CC
intragenic/JJ
SNPs/NNS
(/(
deep/RB
gray/NN
)/)
./.
====================
(/(
B/NN
)/)
Q-Q/NN
plots/NNS
of/IN
association/NN
p-values/NNS
for/IN
MHC/NN
binary/NN
markers/NNS
(/(
black/JJ
)/)
,/,
MHC/NN
binary/NN
markers/NNS
with/IN
allele/NN
frequencies/NNS
(/(
AF/NN
)/)
≥0.05/NN
(/(
red/JJ
)/)
,/,
and/CC
genome-wide/NN
SNPs/NNS
(/(
blue/JJ
)/)
./.
====================
Red/VBN
line/NN
denotes/VBZ
the/DT
expected/VBN
values/NNS
under/IN
no/DT
inflation/NN
./.
====================
MAF/NN
,/,
minor/JJ
allele/NN
frequency/NN
./.
====================
Summary/JJ
statistics/NNS
of/IN
MAF/NN
for/IN
single-nucleotide/JJ
polymorphisms/NNS
====================
Summary/JJ
statistics/NNS
of/IN
HLA/NN
AF/NN
====================
